Abstracts tagged "Validity"

Abstract Number: 030 • 2023 Pediatric Rheumatology Symposium
International Validation of the Total Morbidity Score for Juvenile Localized Scleroderma: 2023 Update
Christina ZIgler¹, Debra Henke², Clare Pain³, Hanna Lythgoe³, Kaveh Ardalan², Kathryn Torok⁴ and Suzanne Li⁵, ¹Duke, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare condition causing inflammation and fibrosis that may impair health-related quality of life (HRQoL). Recent studies demonstrate extracutaneous…
Abstract Number: 2456 • 2019 ACR/ARP Annual Meeting
Validity of Patient-reported Cardiovascular Events in a Large Longitudinal Cohort of Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Vinod Chandran ², Dafna Gladman ³ and Lihi Eder ⁴, ¹University of Toronto, Women's College Hospital, University Health Network, Toronto, ON, Canada, ²University Health Network, University of Toronto, Toronto, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁴Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada
Background/Purpose: Valuable information on cardiovascular disease outcomes can be obtained from large cohort studies. Such studies often rely on self-reported events, which are best validated…
Abstract Number: 2454 • 2019 ACR/ARP Annual Meeting
PROMIS Profile29 Differentiates Active Disease from Treat-to-Target State in Psoriatic Arthritis
Ana-Maria Orbai¹, Rebecca Manno ², Jamie Perin ³, Noori Kim ⁴, Katherine C. Smith ⁵, Albert W Wu ⁶, Clifton Bingham ⁷ and Uzma Haque ², ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ³Johns Hopkins University School of Public Health, Department of International Health, Baltimore, ⁴Johns Hopkins University School of Medicine, Department of Dermatology, Baltimore, MD, ⁵Johns Hopkins University Bloomberg School of Public Health, Department of Health, Behavior and Society, Baltimore, MD, ⁶Johns Hopkins University Bloomberg School of Public Health, Department of Health Policy and Management, Baltimore, MD, ⁷Johns Hopkins University, Baltimore, MD
Background/Purpose: Psoriatic arthritis (PsA) symptoms and quality of life are core domains for PsA assessment1. The PROMIS Profile29 measures symptoms and quality of life using…
Abstract Number: 200 • 2018 ACR/ARHP Annual Meeting
Validation of the Ers-RA Risk Score in a Dutch Population
Milad Baniaamam¹ and Michael Nurmohamed², ¹Department of rheumatology, Amsterdam Rheumatology immunology Center | Reade and VU University Medical Center Amsterdam, Netherlands, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: The most frequent cause of death in patients with chronic rheumatoid arthritis (RA) is of cardiovascular (CV) origin. CV risk prediction scores in the…
Abstract Number: 226 • 2018 ACR/ARHP Annual Meeting
Representation of Elderly People and Women in Rheumatoid Arthritis and Osteoarthritis Trials: A Systematic Review and Meta-Analysis Comparing Clinical Trials with Population-Based Studies
Andriko Palmowski¹, Thomas Buttgereit^1,2, Yannick Palmowski³, Sabrina Mai Nielsen^4,5, Maarten Boers⁶, Robin Christensen^4,5 and Frank Buttgereit¹, ¹Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ²Department of Dermatology, Venerology and Allergology, Charité – University Medicine Berlin, Berlin, Germany, ³Center for Musculoskeletal Surgery, Charité – University Medicine Berlin, Berlin, Germany, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁶Department of Epidemiology and Biostatistics, and Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Elderly people (as commonly defined by an age of ≥65 years) and women have been reported to be underrepresented in clinical trials of various…
Abstract Number: 292 • 2018 ACR/ARHP Annual Meeting
Derivation of a National Rheumatoid Arthritis Cohort in the Veterans Health Administration and Validation with the Veterans Affairs Rheumatoid Arthritis Registry
Bryant R. England¹, Punyasha Roul², Brian Sauer³, Shaobo Pei⁴, Grant W. Cannon⁵, Joshua Baker⁶ and Ted R. Mikuls⁷, ¹Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁴University of Utah, Salt Lake City, UT, ⁵Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁶Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ⁷VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The Veterans Health Administration health system represents the largest integrated healthcare system in the U.S. and maintains robust administrative and clinical data that can…
Abstract Number: 458 • 2018 ACR/ARHP Annual Meeting
Validation of the 2012 Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria Compared to the 1997 Acr Criteria and 2017 Candidate Weighted Criteria for Lupus in Pediatric Patients
Meiqian Ma¹, Jane Cerise², B. Anne Eberhard³ and Joyce Hui-Yuen⁴, ¹Pediatric Rheumatology, Cohen Children's Medical Center of New York, Lake Success, NY, ²Biostatistics, The Feinstein Institute for Medical Research, Manhasset, NY, ³Pediatric Rheumatology, Cohen Children's Medical center, Lake Success, NY, ⁴Pediatric Rheumatology, Cohen Children's Medical Center, Lake Success, NY
Background/Purpose: Different classification criteria for systemic lupus erythematosus (SLE) have been proposed over many years. The most widely used and accepted criteria have been the…
Abstract Number: 641 • 2018 ACR/ARHP Annual Meeting
Construct Validity of the Swollen and Tender Joint Counts for the Measurement of MSK Disease Activity in Psoriatic Arthritis
Ali Duarte-Garcia¹, Lihi Eder², Alisa Stephens-Shields³, Niti Goel⁴, Maarten de Wit⁵, Dafna D Gladman⁶, Oliver FitzGerald⁷, Philip Helliwell⁸, Ying Ying Leung⁹, Philip J. Mease¹⁰, Ana-Maria Orbai¹¹, Beverly Shea¹², Vibeke Strand¹³, William Tillett¹⁴, Laura C. Coates¹⁵ and Alexis Ogdie¹⁶, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, ²Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ³Department of Biostatistics, University of Pennsylvania, Philadelphia, PA, ⁴Kezar Life Sciences; Duke University School of Medicine, Durham, NC, ⁵EULAR standing committee of PARE, Zurich, Switzerland, ⁶Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁷Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ⁸LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁹North District Hospital, Hong Kong, China, ¹⁰Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ¹¹Johns Hopkins University School of Medicine, Baltimore, MD, ¹²University of Ottawa, Ottawa, ON, Canada, ¹³Stanford University School of Medicine, Palo Alto, CA, ¹⁴Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, United Kingdom, ¹⁵University of Oxford, Oxford, United Kingdom, ¹⁶Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Joint counts are central to the measurement of musculoskeletal disease activity in psoriatic arthritis (PsA). Few studies have addressed whether the three most commonly…
Abstract Number: 1406 • 2018 ACR/ARHP Annual Meeting
Longitudinal Construct Validity of the Psaid Individual Items: Can We Eliminate Other Questionnaires If Using the Psaid?
Jessica Walsh¹, Jose U. Scher², Soumya M. Reddy³, M. Elaine Husni⁴ and Alexis Ogdie⁵, ¹University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, ²New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ⁵Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Psoriatic Arthritis Impact of Disease (PsAID) questionnaire is a patient reported measure of disease impact. The 12-item questionnaire has many advantages including demonstrated…
Abstract Number: 1606 • 2018 ACR/ARHP Annual Meeting
The 66/68 Joint Count for the Measurement of MSK Disease Activity/Peripheral Joint Activity in Psa: A Grappa-Omeract Working Group Initiative
Ali Duarte-Garcia¹, Lihi Eder², Niti Goel³, Robin Christensen⁴, Maarten de Wit⁵, Oliver FitzGerald⁶, Dafna D Gladman⁷, Richard Holland⁸, Ying Ying Leung⁹, Christine Lindsay¹⁰, Neil McHugh¹¹, Philip J. Mease¹², Ana-Maria Orbai¹³, Beverly Shea¹⁴, Vibeke Strand¹⁵, William Tillett¹⁶, Laura C. Coates¹⁷ and Alexis Ogdie¹⁸, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, ²Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ³Kezar Life Sciences; Duke University School of Medicine, Durham, NC, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, ⁵EULAR standing committee of PARE, Zurich, Switzerland, ⁶Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Royal Prince Alfred Hospital Medical Centre, Sydney, Australia, ⁹North District Hospital, Hong Kong, China, ¹⁰Medical Affairs, Amgen Inc, Thousand Oaks, CA, ¹¹Rheumatology, Royal National Hospital, Bath, Great Britain, ¹²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ¹³Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵Stanford University School of Medicine, Palo Alto, CA, ¹⁶Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, United Kingdom, ¹⁷University of Oxford, Oxford, United Kingdom, ¹⁸Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: A psoriatic arthritis (PsA) core domain set to be measured in randomized controlled trials (RCT) and longitudinal observational studies (LOS) was developed by Group…
Abstract Number: 2208 • 2018 ACR/ARHP Annual Meeting
Novel Fluorescence Optical Imaging Scoring System of Inflammation in the Hand and Wrist Is in Patients with Rheumatoid Arthritis – Agreement with Ultrasonography and Sensitivity to Change
Mads Ammitzbøll-Danielsen¹, Daniel Glinatsi¹, Lene Terslev² and Mikkel Østergaard^3,4, ¹Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ²Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, ³Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁴Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Fluorescence optical imaging (FOI) has been used for assessment of inflammation in the hands and has in several cross sectional studies been compared with…
Abstract Number: 2978 • 2018 ACR/ARHP Annual Meeting
Performance of the 2017 European League Against Rheumatism / American College of Rheumatology (EULAR/ACR) Classification Criteria for Adult Idiopathic Inflammatory Myopathies (IIM) in an Australian Cohort
Queenie Luu¹, Jessica Day^2,3, Alix Hall⁴, Vidya Limaye^2,5 and Gabor Major^6,7, ¹Rheumatology, Bone and Joint Institute, John Hunter Hospital, New Lambton Heights, Australia, ²Rheumatology, The Royal Adelaide Hospital, Adelaide, Australia, ³School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ⁴Hunter Medical Research Institute, New Lambton Heights, Australia, ⁵Discipline of Medicine, University of Adelaide, South Australia, Adelaide, Australia, ⁶Rheumatology, Bone and Joint Institute, John Hunter Hospital, Newcastle, Australia, ⁷University of Newcastle, Newcastle, Australia, Newcastle, Australia
Background/Purpose: EULAR/ACR recently approved classification criteria for idiopathic inflammatory myopathies (IIM) with 93% sensitivity and 88% specificity. An acknowledged limitation of the study is the…
Abstract Number: 352 • 2017 ACR/ARHP Annual Meeting
Psychometric Features of a New Methotrexate (MTX)-Specific Adherence Tool for Use in the Management of Patients with Rheumatoid Arthritis (RA): Preliminary Results from an Online Patient Community
Elodie de Bock¹, Corrado Bernasconi², Tan P. Pham¹, Ana Maria Rodriguez³, Khaled Sarsour⁴, J. Michael Nebesky² and Christine de la Loge¹, ¹Mapi, Lyon, France, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Patients Like Me (PLM), Cambridge, MA, ⁴Genentech, South San Francisco, CA
Background/Purpose: F. Hoffmann-La Roche Ltd. and Mapi collaborated to develop a medication adherence measure among RA patients taking MTX—the Methotrexate Experience Questionnaire (MEQ). The MEQ…
Abstract Number: 1284 • 2017 ACR/ARHP Annual Meeting
The Localized Scleroderma Quality of Life Instrument (LoSQI): Initial Validation in Pediatric Localized Scleroderma
Christina K. Zigler¹, Kaveh Ardalan², Kaila Schollaert-Fitch³, Heidi Jacobe⁴ and Kathryn S. Torok³, ¹Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ³Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: There is a current need to integrate health related quality of life (HRQoL) into outcomes for clinical trials (Chang & Reeve, 2005). For pediatric…
Abstract Number: 1805 • 2017 ACR/ARHP Annual Meeting
Construct Validity of RAPID3 for Measurement of Disease Activity in Psoriatic Arthritis
Jessica A. Walsh¹, Christine Willinger², M. Elaine Husni³, Soumya M. Reddy⁴, Jose U. Scher⁵ and Alexis Ogdie⁶, ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²University of Pennsylvania, Philadelphia, PA, ³Cleveland Clinic, Cleveland, OH, ⁴Department of Medicine, Division of Rheumatology *contributed equally, New York University School of Medicine, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Routine Assessment of Patient Index Data (RAPID3) was developed and validated for rheumatoid arthritis (RA). Little data exist on the use of RAPID3…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].